



# A review: Brief insight into Polycystic Ovarian syndrome

Jeshica Bulsara<sup>a,\*</sup>, Priyanshi Patel<sup>b</sup>, Arun Soni<sup>b</sup>, Sanjeev Acharya<sup>b</sup>

<sup>a</sup> Research Scholar at SSR College of Pharmacy, sayli, Silvassa

<sup>b</sup> Faculty at SSR College of Pharmacy, sayli, Silvassa

## ARTICLE INFO

### Keywords:

Polycystic ovary syndrome  
Treatment  
Anovulation  
Insulin resistance

## ABSTRACT

Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder with the underline indication of ovarian cysts, anovulation, and endocrine variation affecting the women. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide. The predisposing risk factors include genetics, neuroendocrine, lifestyle/environment, obesity that contributes to the development of PCOS. The pathophysiological aspect of PCOS mainly focuses on hormonal dysfunction, insulin resistance, and hyperandrogenism leading to impaired folliculogenesis which arise the risk for associated comorbidities like endometrial cancer, type II diabetes. This review highlights a brief overview of risk and pathophysiological treatment with drugs acting on anovulation, infertility plus clinical symptoms of PCOS.

## 1. Introduction

Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder distinguished by the manifestation of ovarian cysts, anovulation, and endocrine variation that severely impact the life of a woman (Escobar-Morreale, 2018, Franks, 1995). The disturbance in the reproductive hormones like LH, FSH, estrogen, testosterone interrupts the normal menstrual cycle and would lead to oligomenorrhoea, amenorrhoea like irregularities.

According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide (Bharathi et al., 2017). PCOS is diagnosed with hyperandrogenism, menstrual irregularities, and varying size of cysts in ovaries, although substantial differences exist between individuals. This multifactorial condition initially develops in adolescents who are at high risk for the emergence of several comorbidities including obesity, type II diabetes, infertility, endometrial dysplasia, cardiovascular disorders, and psychotic disorders (El Hayek et al., 2016, Goodarzi et al., 2011).


Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are listed below in Fig. 1 (Lizneva et al., 2016, Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004). Other than three diagnostic criteria, Anti-Müllerian hormone (AMH) is also a marked hormonal indicator and important in maturation and development of ovarian follicles in PCOS women (Broekmans et al., 2008). Over secretion of AMH hinders the follicular development which results into ovarian malfunction.

## 2. Pathophysiology and risk considerations

The marked feature of this condition is the abundance of androgen found in PCOS patients. Hyperandrogenism is evidenced by raised levels of free(unbound) testosterone in the bloodstream, a key hormone contributing to the pathophysiology of PCOS. This complex condition is deconstructed into its main pathophysiological elements (Ibáñez et al., 2017). The predisposing risk factors include genetics, neuroendocrine, lifestyle/environment, obesity that contribute to the development of Polycystic syndrome as depicted in Fig. 2. Some women have a higher risk of developing PCOS due to predominant genes (van Hooff and Lambalk, 1998). Several data on genome-wide association revealed specific loci and alleles that play a major role in PCOS phenotype identification (Hayes et al., 2015, Shi et al., 2012, Dumesic et al., 2015). Environmental factors including physical exercise, lifestyle, and food may vary widely according to the population (Escobar-Morreale et al., 2005). Environmental factors also include endocrine-disrupting chemicals and glycotoxins that may cause genetic variance and disruption of the metabolic and reproductive pathways, which can develop PCOS phenotypes and related complications (Rutkowska and Diamanti-Kandarakis, 2016). Androgen exposure can impede the hormone levels to increase the high pulse frequency of GnRH affecting the LH: FSH proportion and leads to follicular arrest and dysplasia (Dumesic et al., 2015, Cheung, 2010).


These factors lead to the cause of hyperinsulinemia, hyperandrogenism, oxidative stress, irregular periods eventually upsurging the metabolic syndrome. PCOS was named so because it indicated multiple

\* Corresponding author: Ms. Jeshica P. Bulsara, SSR College of Pharmacy, sayli, Silvassa, Dadra nagar haveli-396230.  
E-mail address: [jeshicabulsara396@gmail.com](mailto:jeshicabulsara396@gmail.com) (J. Bulsara).



**Fig. 1.** Summary of diagnostic criteria for PCOS.

Abbreviations: AE-PCOS: Androgen Excess and PCOS society; ASRM: American Society of Reproductive Medicine; ESHRE: European Society for Human Reproduction and Embryology; HA: Hyperandrogenism; OD: Ovulatory dysfunction; PCOM: Polycystic ovarian morphology (12 follicles and 2-9 mm in each ovary).



**Fig. 2.** PCOS risk change factors.




Fig. 3. Schematic depiction of PCOS linked mechanism. (Walters et al., 2018, Barber et al., 2016, Rojas et al., 2014). Abbreviations - IGF-1- insulin-like growth factor, LH-luteinizing hormone, FSH-follicle stimulating hormone.

ovarian cysts (undeveloped follicles) on ultrasound examination. The follicles evolved from primitive follicles, but due to disrupted ovarian function, the development ceased at an early stage (Fig. 3).

## 2.1. PCOS and Hyperandrogenism

Impaired folliculogenesis is the result of surplus androgens that disrupt normal androgen synthesis. The excess androgens promote the development of primordial follicles and increase in the antral follicles at the early gonadotropin stage (Rosenfield and Ehrmann, 2016). The secretion of GnRH from the hypothalamus will activate the gonadotropin hormone release from the pituitary. Luteinizing hormone activates the LH receptor to promote androgen production in ovarian theca cells, and the follicular stimulating hormone acts on the FSH receptor simultaneously in the ovarian granulosa cells to transform the androgens to estrogens, which promote the follicle growth. (Ashraf et al., 2019). It has been assumed that the dysregulation in the neuroendocrine system results in an imbalance of the hypothalamic-pituitary-ovarian axis leading to a surplus level of gonadotropin. The rise in the GnRH promotes the production of LH over FSH, resulting in a marked hormonal increase in the LH:FSH ratio in PCOS (Walters et al., 2018, Tsutsumi and Webster, 2009).

## 2.2. Insulin resistance and Type 2 diabetes

Hyperinsulinemia is the root cause of excess androgens as insulin directly stimulates the action of LH and raise the GnRH indirectly (Puttabayappa and Padmanabhan, 2018, Barber et al., 2016). Insulin decreases the sex hormone binding globulin (SHBG), a main circulatory protein controlling the testosterone levels. So reduced SHBG would result in a raised level of free androgens that produce clinical manifestations like hirsutism, alopecia, and acne (Rojas et al., 2014). Insulin resistance can cause dyslipidemia and the patients with PCOS are at high risk for cardiovascular disease and diabetes (Rocha et al., 2019, McCartney and Marshall, 2016). In women with type 1 diabetes, the prevalence of PCOS is 19%, 37%, 41% according to NIH criteria, AE-PCOS definition,

and ESHRE/ASRM criteria respectively (Escobar-Morreale and Roldán-Martín, 2016). According to a cross-sectional study in U.S. women, the prevalence of IGT is up to 35% and T2D is up to 10% (Legro et al., 1999). Several studies revealed that controlling insulin resistance eventually would decrease the excess androgens and improve the condition (Ashraf et al., 2019, Baillargeon et al., 2004).

## 2.3. Obesity and PCOS

Obesity has been correlated with abnormal hypothalamic-pituitary-ovarian axis function leading to PCOS development (Legro, 2012). Obesity is linked to hyperinsulinemia which further increases the lipid profile, glucose intolerance in PCOS patients. Obesity augments the androgen production by stimulating LH, which in turn leads to hyperandrogenism (Glueck and Goldenberg, 2019). Leptin, an appetite-controlling adipokine has a direct impact on the neuroendocrine and reproductive function of obese PCOS women (Rojas et al., 2014, Barber et al., 2006). Furthermore, hyperleptinemia may hinder ovarian follicular growth (Barber et al., 2006). So, decreasing the visceral fat would control the appetite, glucose levels, lipolysis, and increase the SHBG, thereby regulating the androgen action in the ovary.

## 3. Therapeutic options for PCOS

To date, there is no pharmacological therapy that can cure the syndrome but some interventional medications are used to treat the clinical symptoms of PCOS (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004) as shown in Fig. 4 (Legro et al., 2013). Pharmacological therapies along with a change in the lifestyle ameliorate the overall condition. The treatment strategy varies according to the clinical symptoms and underlying cause which can be divided by treating ovulatory dysfunction, hyperandrogenism, improving insulin resistance, and infertility (Zimmerman et al., 2019).




Fig. 4. Polycystic ovary management protocol stating the treatment options for anovulation and infertility including clinical symptoms.

### 3.1. Oral contraceptives (OCPs)

The OCPs are divided into progesterone-only pills and combined pills containing both estrogen (estradiol dose up to 50µg) and progesterone (norethisterone, desogestrel) (Society, 2018). They are first-line therapy for women who do not want to ovulate and are facing menstrual irregularities. OCPs decrease the circulating androgens by raising the SHBG (Fig. 5) (Geller et al., 2011). Women with PCOS are prone to cancers, but the use of OCPs diminishes the risk of ovarian cancers (Grimes and Economy, 1995). The use of OCPs do not affect insulin resistance but show variability in lipid profiles which may lead to metabolic disturbances (Geller et al., 2011, Halperin et al., 2011). So, the usage of OCPs should be according to the risk grade and stopped immediately if any contradiction occurs.

### 3.2. Antiandrogens

This category includes spironolactone, flutamide, cyproterone acetate which decreases the androgen secretion by androgen receptor inhibition and is preferred as first-line drugs for hirsutism (Badawy and Elnashar, 2011). Spironolactone, an aldosterone antagonist produces an antiandrogenic effect at high doses. Spironolactone alone leads to more frequent menstruation cycles, so it is generally used in combination with OCPs to produce a synergistic effect and overcome the problem (Rittmaster, 1999). Flutamide is a well-tolerated anti-androgen used to treat prostate cancer. It has the same effectiveness as spironolactone




Fig. 5. Mechanism of OCPs.

in managing hirsutism (Badawy and Elnashar, 2011, Rittmaster, 1999, Erenus et al., 1994). Flutamide is used in combination with metformin as it causes hepatotoxicity when used alone (Ibáñez and de Zegher, 2006). Cyproterone acetate is an antiandrogen with potent progestogenic activity (Badawy and Elnashar, 2011, Rittmaster, 1999). Cyproterone acetate in combination with ethinylestradiol is used as a remedy for acne and



hirsutism (Franks et al., 2008). Finasteride is a 5- $\alpha$ -reductase inhibitor showing lower scores of hirsutism (Lakryc et al., 2003). But finasteride is limited for its use in women because of its teratogenic effects. It is used in postmenopausal women or those who do not want to ovulate (Rittmaster, 1999, Pasquali and Gambineri, 2014).

### 3.3. Insulin sensitizers

This class of drugs is generally used to treat PCOS-associated metabolic co-morbidities by decreasing insulin resistance and normalizing insulin levels. By lowering the IR, the associated androgen level will decrease resulting in improvement in the menstrual cycle (Geller et al., 2011).

#### 3.3.1. Metformin

Metformin is a large-scale manufactured biguanide used to treat insulin resistance and reinstate the menstrual irregularities in PCOS (Lauretta et al., 2016). Metformin increases the glucose uptake and its utilization which in turn ameliorates insulin resistance in PCOS patients (Geller et al., 2011, Moghetti et al., 2000). It regulates the glucose level, unlike other insulin-regulating drugs which lead to either hypoglycemia or hyperglycemia as its side effect (Sivalingam et al., 2014). Metformin functions indirectly by lowering the insulin level with a decrease in CYP17 cytochrome activity which is involved in the production of androgens and also increases the SHBG further decrease in the free testosterone (Lashen, 2010, Nestler and Jakubowicz, 1996). The effects of metformin also include slight improvement in the lipid profile of PCOS patients (Wulffelé et al., 2004, Loverro et al., 2002). The use of metformin in pregnancy do not show any teratogenic effect, also reduces inflammation and complications related to pregnancy (Sivalingam et al., 2014, Isoda et al., 2006, Glueck et al., 2002). When combined with clomiphene citrate, the ovulation and pregnancy rate were found to be increased in infertile PCOS patients (Dasari and Pranahita, 2009). Combining metformin with antiandrogens like flutamide shows a synergistic effect in obese PCOS women, though flutamide is not observed safe for laboratory animals (Gambineri et al., 2004, Pasquali and Gambineri, 2006). A beneficial effect was remarked by improving hyperandrogenism in PCOS women when treated with dexamethasone and metformin along with lifestyle modification (Pasquali and Gambineri, 2006, Vanky et al., 2004). Further including metformin in ovulation stimulating regimen for IVF PCOS patients showed better oocyte quality (Qublan et al., 2009). Metformin has a preventive role in the long-term diseases associated with PCOS women including endometrial cancer, type 2 diabetes, cardiovascular diseases, hypertension (Sahra et al., 2008, Salpeter et al., 2008).

#### 3.3.2. Thiazolidinediones (TZDs)

This class is commonly named glitazones comprising of rosiglitazone, pioglitazone which decrease the 11- $\beta$ -HSD enzyme activity responsible for conversion of cortisol (Lauretta et al., 2016, Stabile et al., 2014). They are the second-line choice of drugs for treating PCOS women who are resistant to insulin (Stout and Fugate, 2005). TZDs stimulate peroxisome proliferator-activated receptor-gamma (PPAR $\gamma$ ) that elevates insulin sensitivity in adipose tissue (Day, 1999). TZDs indicated positive effects on the ovulation and pregnancy rate and are used in clomiphene-resistant PCOS women (Stout and Fugate, 2005, Froment and Touraine, 2006, Cataldo et al., 2001). TZDs diminish the excess androgens by increasing the SHBG levels and by redistribution in adipose tissue (Brettenthaler et al., 2004). TZDs decrease the inflammatory mediators that are aggravated more in diabetic and obese women (Haffner et al., 2002). Studies comparing the effect of metformin and TZDs together signified no superiority, both increased the ovulation rate, insulin resistance, and regulation of the menstrual cycle (Yilmaz et al., 2005). TZDs are category C drugs that tend to have a risk to the growing fetus in experimental animals, so their use should be surveilled (Froment and Touraine, 2006).

### 3.4. Ovulation inducing agents

Clomiphene citrate (CC) is the prime choice of drug for treating anovulatory sterile women (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008). CC increases the FSH level by inhibiting the estrogen receptor through a negative feedback mechanism (Badawy and Elnashar, 2011, Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008). It is suggested for the management of anovulatory PCOS patients but pregnancy rates differ significantly according to the BMI, for BMI less than 30 increased the rate of pregnancy and vice-versa (Legro et al., 2007). Chances of multiple pregnancies are up to 8% and risk of hyperstimulation with clomiphene is nil (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008, Eijkemans et al., 2003).

Tamoxifen acts similarly to clomiphene which is used to treat anovulation in patients who fail or not respond to clomiphene citrate (Borenstein et al., 1989, Dhaliwal et al., 2020). Unlike clomiphene, tamoxifen has a positive on the endometrium and cervical mucus (Borenstein et al., 1989). Due to the promising effect on uterine lining by tamoxifen, the combined studies of clomiphene and tamoxifen revealed a marked increase in pregnancy rate (Dhaliwal et al., 2020). There is no variance found in the rate of ovulation or pregnancy with either clomiphene or tamoxifen (Steiner et al., 2005).

Letrozole is an off-label aromatase inhibitor, that obstructs the androgen to estrogen conversion pathway and aid in folliculogenesis by stimulating FSH (Kar, 2013). Letrozole is advantageous over clomiphene as estrogen receptors are not depleted and the antiestrogenic effect on the endometrium is not observed (Casper and MF, 2011). So, letrozole is a better drug option in ovulation induction used as a substitute drug to clomiphene showing similar effects (Holzer et al., 2006). Studies suggest that letrozole is more effective in anovulatory infertility than CC in PCOS patients (Legro et al., 2014). While comparing the two aromatase inhibitors that is anastrozole and letrozole, higher pregnancy rates were found with letrozole (Al-Omari et al., 2004).

Gonadotropins such as recombinant FSH, human menopausal gonadotropin (HMG) are the second-line choice of treatment for anovulatory infertile PCOS women (Melo et al., 2015). Low dose FSH therapy is suitable for ovulation induction and improving pregnancy rates in PCOS patients (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008, Homburg and Howles, 1999). An interventional study indicated that the low-dose step-up HMG protocol gave beneficial results (Andoh et al., 1998). Gonadotropins can be too costly for timely intercourse administration, so instead, intrauterine insemination or in-vitro fertilization is done (Melo et al., 2015, Veltman-Verhulst et al., 2016).

Laparoscopic surgery is a second-line surgical procedure for ovulation in clomiphene-resistant PCOS women or non-responders to clomiphene (Seow et al., 2008). Laparoscopic Ovarian Drilling (LOD) is rupturing the ovary multiple times by laser or diathermy (Farquhar et al., 2012). The risk of multiple pregnancy and hyperstimulation of the ovary is reduced by LOD (Api et al., 2005). Although the long-term risk of LOD includes ovarian adhesion in women (Greenblatt and Casper, 1993). Ovarian drilling leads to a decrease in size and volume of the ovarian tissue, further damaging the ovary but it is concluded through studies that depletion in the ovarian size indicated normal functioning of the ovaries in PCOS women (Amer et al., 2002).

In-vitro fertilization (IVF) is recommended as a third-line choice of therapy for treating infertility in PCOS women without any associated complications linked (Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008, Melo et al., 2015). Adjuvant metformin treatment for a short period of time ameliorates pregnancy rates in PCOS women receiving IVF (Tang et al., 2006). IVF involves complicated procedures with concerning side effects mainly hyperstimulation of the ovary and high-cost treatment (Heijnen et al., 2006).

### 3.5. Lifestyle Intervention

PCOS is a long-term disease with greater chances of other comorbidities like type II diabetes linked with it, so lifestyle modification is the crucial and simple approach for implementation in women with PCOS (Carmina, 2012). Studies revealed that changes in the lifestyle, including diet, exercise, and, attitude have a positive impact on body weight, insulin resistance, and testosterone levels (Moran et al., 2011).

### 4. Conclusion

It is clear from the review that PCOS is a complex condition. The central mechanism is difficult to understand and state. Thereby no treatment can be claimed as a magic bullet as it targets the clinical symptoms rather than curing the syndrome. Alternative drugs such as herbal or medicinal plants should be considered by knowing their mechanism of action. Further investigation regarding pathophysiology and drugs acting on it should be done for improvising the abiding consequence on patient's health. Improvising lifestyle could ease the PCOS related symptoms.

### Declaration of Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Peer Review Summary

Peer Review Summary associated with this article can be found in the online version, at doi:10.1016/j.endmts.2021.100085.

### References

- Al-Omari, W.R., Sulaiman, W.R., Al-Hadithi, N., 2004 Jun. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. *Int. J. Gynecol. Obstetrics* 85 (3), 289–291. doi:10.1016/j.ijgo.2003.11.010.
- Amer, S.A., Banu, Z., Li, T.C., Cooke, ID., 2002 Nov 1. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. *Hum. Reprod.* 17 (11), 2851–2857. doi:10.1093/humrep/17.11.2851.
- Andoh, K., Mizunuma, H., Liu, X., Kamijo, T., Yamada, K., Ibuki, Y., 1998 Nov 1. A comparative study of fixed-dose, step-down, and low-dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. *Fertil. Steril.* 70 (5), 840–846. doi:10.1016/S0015-0282(98)00308-2.
- Api, M., Gorgen, H., Cetin, A., 2005 Mar 1. Laparoscopic ovarian drilling in polycystic ovary syndrome. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 119 (1), 76–81. doi:10.1016/j.ejogrb.2004.07.023.
- Ashraf, S., Nabi, M., Rashid, F., Amin, S., 2019 Dec 1. Hyperandrogenism in polycystic ovary syndrome and role of CYP gene variants: a review. *Egypt. J. Med. Hum. Genetics* 20 (1), 25. doi:10.1186/s43042-019-0031-4.
- Badawy, A., Elnashar, A., 2011. Treatment options for polycystic ovary syndrome. *Int. J. Women's Health* 3, 25 https://dx.doi.org/10.2147%2FJWH.S11304.
- Baillargeon, J.P., Jakubowicz, D.J., Iuorno, M.J., Jakubowicz, S., Nestler, J.E., 2004 Oct 1. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. *Fertil. Steril.* 82 (4), 893–902. doi:10.1016/j.fertnstert.2004.02.127.
- Barber, T.M., McCarthy, M.I., Wass, J.A., Franks, S., 2006 Aug. Obesity and polycystic ovary syndrome. *Clin. Endocrinol. (Oxf)* 65 (2), 137–145. doi:10.1111/j.1365-2265.2006.02587.x.
- Barber, T.M., Dimitriadis, G.K., Andreou, A., Franks, S., 2016 Jun. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. *Clin. Med.* 16 (3), 262 https://dx.doi.org/10.7861/2Fclinmedicine.16-3-262.
- Bharathi, R.V., Swetha, S., Neerajaa, J., Madhavica, J.V., Janani, D.M., Rekha, S.N., Ramya, S., Usha, B., 2017 Dec 1. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. *Middle East Fertility Society Journal* 22 (4), 313–316. doi:10.1016/j.mefs.2017.05.007.
- Borenstein, R., Schwartz, Z.S., Yemini, M., Barash, A., Fienstein, M., Rozenman, D., 1989 May. Tamoxifen treatment in women with failure of clomiphene citrate therapy. *Aust. N. Z. J. Obstet. Gynaecol.* 29 (2), 173–175. doi:10.1111/j.1479-828X.1989.tb01711.x.
- Brettenthaler, N., De Geyter, C., Huber, P.R., Keller, U., 2004 Aug 1. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 89 (8), 3835–3840. doi:10.1210/jc.2003-031737.
- Broekmans, F.J., Visser, J.A., Laven, J.S., Broer, S.L., Themmen, A.P., Fauser, B.C., 2008 Nov 1. Anti-Müllerian hormone and ovarian dysfunction. *Trends in Endocrinol. Metabol.* 19 (9), 340–347. doi:10.1016/j.tem.2008.08.002.
- Carmina, E., 2012 Dec. PCOS: metabolic impact and long-term management. *Minerva Ginecol.* 64 (6), 501 PMID: 23232534.
- Casper, R.F., MF, M., 2011 Dec 1. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. *Clin. Obstet. Gynecol.* 54 (4), 685–695. doi:10.1097/GRF.0b013e3182353d0f.
- Cataldo, N.A., Abbasi, F., McLaughlin, T.L., Lamendola, C., Reaven, G.M., 2001 Nov 1. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. *Fertil. Steril.* 76 (5), 1057–1059. doi:10.1016/S0015-0282(01)02843-6.
- Cheung, AP., 2010 May 1. Polycystic ovary syndrome: a contemporary view. *J. Obstet. Gynaecol. Can* 32 (5), 423–425. doi:10.1016/s1701-2163(16)34493-0.
- Dasari, P., Pranahita, G.K., 2009 Jan. The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. *J. Hum. Reprod. Sci.* 2 (1), 18 10.4103%2F0974-1208.51337.
- Day, C., 1999 Mar. Thiazolidinediones: a new class of antidiabetic drugs. *Diabet. Med.* 16 (3), 179–192. doi:10.1046/j.1464-5491.1999.00023.x.
- Dhaliwal, L.K., Suri, V., Gupta, K.R., Sahdev, S., 2020 May. Tamoxifen: An alternative to clomiphene in women with polycystic ovary syndrome. *J. Hum. Reprod. Sci.* 4 (2), 76 https://dx.doi.org/10.4103%2F0974-1208.86085.
- Dumesic, D.A., Oberfield, S.E., Stener-Victorin, E., Marshall, J.C., Laven, J.S., Legro, R.S., 2015 Oct 1. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. *Endocr. Rev.* 36 (5), 487–525. doi:10.1210/er.2015-1018.
- Eijkemans, M.J., Imani, B., Mulders, A.G., Habbema, J.D., Fauser, B.C., 2003 Nov 1. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). *Hum. Reprod.* 18 (11), 2357–2362. doi:10.1093/humrep/deg459.
- El Hayek, S., Bitar, L., Hamdar, L.H., Mirza, F.G., Daoud, G., 2016 Apr 5. Polycystic ovarian syndrome: an updated overview. *Front. Physiol.* 7, 124. doi:10.3389/fphys.2016.00124.
- Erenus, M., Gürbüz, O., Durmuşoğlu, F., Demircay, Z., Pekin, S., 1994 Apr 1. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. *Fertil. Steril.* 61 (4), 613–616. doi:10.1016/S0015-0282(16)56634-5.
- Escobar-Morreale, H.F., Roldán-Martín, M.B., 2016 Apr 1. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. *Diabetes Care.* 39 (4), 639–648. doi:10.2337/dc15-2577.
- Escobar-Morreale, H.F., Luque-Ramírez, M., San Millán, J.L., 2005 Apr 1. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. *Endocr. Rev.* 26 (2), 251–282. doi:10.1210/er.2004-0004.
- Escobar-Morreale, H.F., 2018 May. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nat. Rev. Endocrinol.* 14 (5), 270. doi:10.1038/nrendo.2018.24.
- Farquhar, C., Brown, J., Marjoribanks, J., 2012. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane database of systematic reviews* (6) doi:10.1002/14651858.CD001122.pub4.
- Franks, S., Layton, A., Glasier, A., 2008 Feb 1. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. *Hum. Reprod.* 23 (2), 231–232. doi:10.1093/humrep/dem379.
- Franks, S., 1995 Sep 28. Polycystic ovary syndrome. *N. Engl. J. Med.* 333 (13), 853–861. doi:10.1056/NEJM199509283331307.
- Froment, P., Touraine, P., 2006 Jan 1. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). *PPAR Res.* 2006. doi:10.1155/PPAR/2006/73986.
- Gambineri, A., Pelusi, C., Genghini, S., Morselli-Labate, A.M., Cacciari, M., Pagotto, U., Pasquali, R., 2004 Feb. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. *Clin. Endocrinol. (Oxf)* 60 (2), 241–249. doi:10.1111/j.1365-2265.2004.01973.x.
- Geller, D.H., Pacaud, D., Gordon, C.M., Misra, M., 2011. Of the Drug and Therapeutics Committee of the Pediatric Endocrine Society (2011). Emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). *Int. J. Pediatr. Endocrinol.* 9. doi:10.1186/1687-9856-2011-9.
- Glueck, C.J., Goldenberg, N., 2019 Mar 1. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. *Metabolism* 92, 108–120. doi:10.1016/j.metabol.2018.11.002.
- Glueck, C.J., Wang, P., Goldenberg, N., 2002 Nov 1. Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. *Hum. Reprod.* 17 (11), 2858–2864. doi:10.1093/humrep/17.11.2858.
- Goodarzi, M.O., Dumesic, D.A., Chazenbalk, G., Azziz, R., 2011 Apr. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat. Rev. Endocrinol.* 7 (4), 219–231. doi:10.1038/nrendo.2010.217.
- Greenblatt, E.M., Casper, R.F., 1993 Nov 1. Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. *Fertil. Steril.* 60 (5), 766–770. doi:10.1016/S0015-0282(16)56273-6.
- Grimes, D.A., Economy, K.E., 1995 Jan 1. Primary prevention of gynecologic cancers. *Am. J. Obstet. Gynecol.* 172 (1), 227–235. doi:10.1016/0002-9378(95)90125-6.
- Haffner, S.M., Greenberg, A.S., Weston, W.M., Chen, H., Williams, K., Freed, M.I., 2002 Aug 6. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. *Circulation* 106 (6), 679–684. doi:10.1161/01.CIR.0000025403.20953.23.
- Halperin, I.J., Sujana Kumar, S., Stroup, D.F., Laredo, S.E., 2011 Jan 1. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. *Hum. Reprod.* 26 (1), 191–201. doi:10.1093/humrep/deq301.
- Hayes, M.G., Urbanek, M., Ehrmann, D.A., Armstrong, L.L., Lee, J.Y., Sisk, R., Kaderli, T., Barber, T.M., McCarthy, M.I., Franks, S., Lindgren, C.M., 2015 Aug 18. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. *Nat. Commun.* 6 (1), 1–3. doi:10.1038/ncomms8502.
- Heijnen, E.M., Eijkemans, M.J., Hughes, E.G., Laven, J.S., Macklon, N.S., Fauser, B.C., 2006 Jan 1. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. *Hum. Reprod. Update* 12 (1), 13–21. doi:10.1093/humupd/dmi036.

- Holzer, H., Casper, R., Tulandi, T., 2006 Feb 1. A new era in ovulation induction. *Fertil. Steril.* 85 (2), 277–284. doi:10.1016/j.fertnstert.2005.05.078.
- Homburg, R., Howles, C.M., 1999 Sep 1. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements. *Hum. Reprod. Update* 5 (5), 493–499. doi:10.1093/humupd/5.5.493.
- Ibáñez, L., de Zegher, F., 2006 May. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. *Hum. Reprod. Update* 12 (3), 243–252. doi:10.1093/humupd/dmi054.
- Ibáñez, L., Oberfield, S.E., Witchel, S., Auchus, R.J., Chang, R.J., Codner, E., Dabaddghao, P., Darendeliler, F., Elbarbary, N.S., Gambineri, A., Rudaz, C.G., 2017. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. *Hormone Res. Paediatr.* 88, 371–395. doi:10.1159/000479371.
- Isoda, K., Young, J.L., Zirlik, A., MacFarlane, L.A., Tsuboi, N., Gerdes, N., Schonbeck, U., Libby, P., 2006 Mar 1. Metformin inhibits proinflammatory responses and nuclear factor- $\kappa$ B in human vascular wall cells. *Arterioscler. Thromb. Vasc. Biol.* 26 (3), 611–617. doi:10.1161/01.ATV.0000201938.78044.75.
- Kar, S., 2013 Apr. Current evidence supporting “letrozole” for ovulation induction. *J. Hum. Reprod. Sci.* 6 (2), 93 https://dx.doi.org/10.4103%2F0974-1208.117166.
- Lakryc, E.M., Motta, E.L., Soares, J.M., Haidar, M.A., Rodrigues de Lima, G., Baracat, E.C., 2003 Jan 1. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. *Gynecol. Endocrinol.* 17 (1), 57–63. doi:10.1080/gye.17.1.57.63.
- Lashen, H., 2010 Aug. Role of metformin in the management of polycystic ovary syndrome. *Therapeutic Adv. Endocrinol. Metabol.* 1 (3), 117–128. doi:10.1177%2F2042018810380215.
- Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., Appetecchia, M., 2016 Jan 1. Insulin-sensitizers, polycystic ovary syndrome and gynaecological cancer risk. *Int. J. Endocrinol.* 2016. doi:10.1155/2016/8671762.
- Legro, R.S., Kuneselman, A.R., Dodson, W.C., Dunaif, A., 1999 Jan 1. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J. Clin. Endocrinol. Metabol.* 84 (1), 165–169. doi:10.1210/jcem.84.1.5393.
- Legro, R.S., Barnhart, H.X., Schlaff, W.D., Carr, B.R., Diamond, M.P., Carson, S.A., Steinkampf, M.P., Coutifaris, C., McGovern, P.G., Cataldo, N.A., Gosman, G.G., 2007 Feb 8. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N. Engl. J. Med.* 356 (6), 551–566. doi:10.1056/NEJMoa063971.
- Legro, R.S., Arslanian, S.A., Ehrmann, D.A., Hoeger, K.M., Murad, M.H., Pasquali, R., Welt, C.K., 2013 Dec 1. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metabol.* 98 (12), 4565–4592. doi:10.1210/jc.2013-2350.
- Legro, R.S., Brzyski, R.G., Diamond, M.P., Coutifaris, C., Schlaff, W.D., Casson, P., Christman, G.M., Huang, H., Yan, Q., Alvero, R., Haisenedler, D.J., 2014 Jul 10. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. *N. Engl. J. Med.* 371, 119–129. doi:10.1056/NEJMoa1313517.
- Legro, R.S., 2012 Dec. Obesity and PCOS: implications for diagnosis and treatment. In *Seminars in reproductive medicine*, Vol. 30. NIH Public Access, p. 496 https://dx.doi.org/10.1055%2Fs-0032-1328878.
- Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., Azziz, R., 2016 Jul 1. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertil. Steril.* 106 (1), 6–15. doi:10.1016/j.fertnstert.2016.05.003.
- Loverio, G., Lorusso, F., De Pergola, G., Nicolardi, V., Mei, L., Selvaggi, L., 2002 Jan 1. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. *Gynecol. Endocrinol.* 16 (3), 217–224. doi:10.1080/gye.16.3.217.224.
- McCartney, C.R., Marshall, J.C., 2016 Jul 7. Polycystic ovary syndrome. *N. Engl. J. Med.* 375 (1), 54–64. doi:10.1056/NEJMcip1514916.
- Melo, A.S., Ferriani, R.A., Navarro, P.A., 2015 Nov. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. *Clinics* 70 (11), 765–769. doi:10.6061/clinics/2015(11)09.
- Moggetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolini, E., Muggeo, M., 2000 Jan 1. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J. Clin. Endocrinol. Metabol.* 85 (1), 139–146. doi:10.1210/jcem.85.1.6293.
- Moran, L.J., Hutchison, S.K., Norman, R.J., Teede, H.J., 2011. Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database of Systematic Reviews* (7) doi:10.1016/S0140-6736(05)78231-3.
- Nestler, J.E., Jakubowicz, D.J., 1996 Aug 29. Decreases in ovarian cytochrome P450c17 $\alpha$  activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. *N. Engl. J. Med.* 335 (9), 617–623. doi:10.1056/NEJM19960829350902.
- Pasquali, R., Gambineri, A., 2006 Jun 1. Insulin-sensitizing agents in polycystic ovary syndrome. *Eur. J. Endocrinol.* 154 (6), 763–775. doi:10.1530/eje.1.02156.
- Pasquali, R., Gambineri, A., 2014 Feb 1. Therapy of endocrine disease: Treatment of hirsutism in the polycystic ovary syndrome. *Eur. J. Endocrinol.* 170 (2). doi:10.1530/EJE-13-0585, R75-90.
- Puttabyatappa, M., Padmanabhan, V., 2018 Nov 1. Ovarian and extra-ovarian mediators in the development of polycystic ovary syndrome. *J. Mol. Endocrinol.* 61 (4). doi:10.1530/JME-18-0079, R161-84.
- Qublan, H.S., Al-Khaderei, S., Abu-Saleem, A.N., Al-Zpoon, A., Al-Khateeb, M., Al-Ibrahim, N., Megdadi, M., Al-Ahmad, N., 2009 Jan 1. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. *J. Obstet. Gynaecol.* 29 (7), 651–655. doi:10.1080/01443610903147576.
- Rittmaster, R.S., 1999 Jun 1. Antiandrogen treatment of polycystic ovary syndrome. *Endocrinol. Metab. Clin. North Am.* 28 (2), 409–421. doi:10.1016/S0889-8529(05)70077-3.
- Rocha, A.L., Oliveira, F.R., Azevedo, R.C., Silva, V.A., Peres, T.M., Candeido, A.L., Gomes, K.B., Reis, F.M., 2019. Recent advances in the understanding and management of polycystic ovary syndrome. *F1000Research* 8 https://dx.doi.org/10.12688/f1000research.15318.1.
- Rojas, J., Chávez, M., Olivar, L., Rojas, M., Morillo, J., Mejías, J., Calvo, M., Bermúdez, V., 2014 Jan 28. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiological labyrinth. *Int. J. Reprod. Med.* 2014. doi:10.1155/2014/719050.
- Rosenfield, R.L., Ehrmann, D.A., 2016 Oct 1. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr. Rev.* 37 (5), 467–520. doi:10.1210/er.2015-1104.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004 Jan 1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum. Reprod.* 19 (1), 41–47. doi:10.1016/j.fertnstert.2003.10.004.
- Rutkowska, A.Z., Diamanti-Kandarakis, E., 2016 Sep 15. Polycystic ovary syndrome and environmental toxins. *Fertil. Steril.* 106 (4), 948–958. doi:10.1016/j.fertnstert.2016.08.031.
- Sahra, I.B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J.F., Le Marchand-Brustel, Y., Bost, F., 2008 Jun. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. *Oncogene* 27 (25), 3576–3586. doi:10.1038/sj.onc.1211024.
- Salpeter, S.R., Buckley, N.S., Kahn, J.A., Salpeter, E.E., 2008 Feb 1. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. *Am. J. Med.* 121 (2), 149–157. doi:10.1016/j.amjmed.2007.09.016.
- Seow, K.M., Juan, C.C., Hwang, J.L., Ho, L.T., 2008 Jan. Seminars in reproductive medicine. In: *Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects*, Vol. 26. © Thieme Medical Publishers, pp. 101–110. doi:10.1055/s-2007-992930.
- Shi, Y., Zhao, H., Shi, Y., Cao, Y., Yang, D., Li, Z., Zhang, B., Liang, X., Li, T., Chen, J., Shen, J., 2012 Sep. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. *Nat. Genet.* 44 (9), 1020. doi:10.1038/ng.2384.
- Sivalingam, V.N., Myers, J., Nicholas, S., Balen, A.H., Crosbie, E.J., 2014 Nov 1. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. *Hum. Reprod. Update* 20 (6), 853–868. doi:10.1093/humupd/dmu037.
- Society, T.P., 2018 Apr. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. *J. Hum. Reprod. Sci.* 11 (2), 96 https://dx.doi.org/10.4103%2Fjhrs.jhrs.72.18.
- Stabile, G., Borrielli, I., Arsenio, A.C., Bruno, L.M., Benavenga, S., Giunta, L., La Marca, A., Volpe, A., Pizzo, A., 2014 Jun 1. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. *J. Pediatr. Adolesc. Gynecol.* 27 (3), 177–182. doi:10.1016/j.jpaa.2013.09.015.
- Steiner, A.Z., Terplan, M., Paulson, R.J., 2005 Jun 1. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. *Hum. Reprod.* 20 (6), 1511–1515. doi:10.1093/humrep/deh840.
- Stout, D.L., Fugate, S.E., 2005 Feb. Thiazolidinediones for treatment of polycystic ovary syndrome. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 25 (2), 244–252. doi:10.1592/phco.25.2.244.56943.
- Tang, T., Glanville, J., Orsi, N., Barth, J.H., Balen, A.H., 2006 Jun 1. The use of metformin for women with PCOS undergoing IVF treatment. *Hum. Reprod.* 21 (6), 1416–1425. doi:10.1093/humrep/del025.
- Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008 Mar 1. Consensus on infertility treatment related to polycystic ovary syndrome. *Hum. Reprod.* 23 (3), 462–477. doi:10.1016/j.fertnstert.2007.09.041.
- Tsutsumi, R., Webster, N.J., 2009. GnRH pulsatility, the pituitary response and reproductive dysfunction. *Endocr. J.* 56 (6), 729–737. doi:10.1507/endocrj.K09E-185.
- van Hooff, M.H., Lambalk, C.B., 1998 Jan 24. Length of gestation and polycystic ovaries in adulthood. *Lancet North Am. Ed.* 351 (9098), 296. doi:10.1016/S0140-6736(05)78231-3.
- Vanky, E., Salvesen, K.Å., Carlsen, S.M., 2004 Mar 1. Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. *Hum. Reprod.* 19 (3), 529–533. doi:10.1093/humrep/deh103.
- Veltman-Verhulst, S.M., Hughes, E., Ayeleke, R.O., Cohlen, B.J., 2016. Intra-uterine insemination for unexplained subfertility. *Cochrane Database of Systematic Reviews* (2) doi:10.1002/14651858.CD001838.
- Walters, K.A., Gilchrist, R.B., Ledger, W.L., Teede, H.J., Handelsman, D.J., Campbell, R.E., 2018 Dec 1. New perspectives on the pathogenesis of PCOS: neuroendocrine origins. *Trends in Endocrinol. Metabol.* 29 (12), 841–852. doi:10.1016/j.tem.2018.08.005.
- Wulffélé, E.M., Kooy, A., De Zeeuw, D., Stehouwer, C.D., Gansevoort, R.T., 2004 Jul. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. *J. Intern. Med.* 256 (1), 1–4. doi:10.1111/j.1365-2796.2004.01328.x.
- Yilmaz, M., Karakoç, A., Törüner, F.B., Çakır, N., Tiras, B., Ayvaz, G., Arslan, M., 2005 Jan 1. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. *Gynecol. Endocrinol.* 21 (3), 154–160. doi:10.1080/09513590500231627.
- Zimmerman, L.D., Setton, R., Pereira, N., Rosenwaks, Z.E., 2019 Jun 1. Contemporary Management of Polycystic Ovarian Syndrome. *Clin. Obstet. Gynecol.* 62 (2), 271–281. doi:10.1097/GRF.0000000000000449.